GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aequus Pharmaceuticals Inc (OTCPK:AQSZF) » Definitions » Cash Ratio

Aequus Pharmaceuticals (Aequus Pharmaceuticals) Cash Ratio : 0.04 (As of Mar. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Aequus Pharmaceuticals Cash Ratio?

The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. Aequus Pharmaceuticals's Cash Ratio for the quarter that ended in Mar. 2024 was 0.04.

Aequus Pharmaceuticals has a Cash Ratio of 0.04. It indicates that there are more current liabilities than Cash, Cash Equivalents, Marketable Securities, and the company does not have sufficient cash on hand to pay off its short-term debt.

The historical rank and industry rank for Aequus Pharmaceuticals's Cash Ratio or its related term are showing as below:

AQSZF' s Cash Ratio Range Over the Past 10 Years
Min: 0.03   Med: 1.17   Max: 8.23
Current: 0.04

During the past 11 years, Aequus Pharmaceuticals's highest Cash Ratio was 8.23. The lowest was 0.03. And the median was 1.17.

AQSZF's Cash Ratio is ranked worse than
91.17% of 997 companies
in the Drug Manufacturers industry
Industry Median: 0.59 vs AQSZF: 0.04

Aequus Pharmaceuticals Cash Ratio Historical Data

The historical data trend for Aequus Pharmaceuticals's Cash Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aequus Pharmaceuticals Cash Ratio Chart

Aequus Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.02 4.47 0.97 0.11 0.04

Aequus Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
Cash Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.11 - 0.03 0.04 0.04

Competitive Comparison of Aequus Pharmaceuticals's Cash Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Aequus Pharmaceuticals's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aequus Pharmaceuticals's Cash Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aequus Pharmaceuticals's Cash Ratio distribution charts can be found below:

* The bar in red indicates where Aequus Pharmaceuticals's Cash Ratio falls into.



Aequus Pharmaceuticals Cash Ratio Calculation

The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.

Aequus Pharmaceuticals's Cash Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash Ratio (A: Dec. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=0.127/3.575
=0.04

Aequus Pharmaceuticals's Cash Ratio for the quarter that ended in Mar. 2024 is calculated as:

Cash Ratio (Q: Mar. 2024 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=0.179/4.054
=0.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Aequus Pharmaceuticals  (OTCPK:AQSZF) Cash Ratio Explanation

The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.

The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.

In general, the higher the cash ratio, the better the company's liquidity position.


Aequus Pharmaceuticals Cash Ratio Related Terms

Thank you for viewing the detailed overview of Aequus Pharmaceuticals's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Aequus Pharmaceuticals (Aequus Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
200 Granville Street, Suite 2820, Vancouver, BC, CAN, V6C 1S4
Aequus Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The firm's operating segments are the Commercial platform and Development pipeline. It generates a majority of its revenue from the Commercial platform segment. The Company earns revenues from the sale of dry eye products and by providing promotional services to sell third-party-owned products, namely Tacrolimus IR and Vistitan.

Aequus Pharmaceuticals (Aequus Pharmaceuticals) Headlines

From GuruFocus

Aequus Provides Update on Delay in Filing Annual Financial Statements

By GuruFocusNews GuruFocusNews 07-06-2022

Aequus Provides General Update and Reports Record 2021 Financial Results

By GuruFocusNews GuruFocusNews 07-01-2022

Aequus Provides Update on Delay in Filing Annual Financial Statements

By GuruFocusNews GuruFocusNews 07-06-2022

Aequus Provides General Update and Reports Record 2021 Financial Results

By GlobeNewswire GlobeNewswire 07-01-2022

Aequus Resumes Trading on TSX Venture Exchange

By PurpleRose PurpleRose 07-13-2022

Aequus Announces Zimed PF Website Launch

By Marketwired 08-22-2023